Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of ensifentrine in non-cystic fibrosis bronchiectasis
MOH_2026-09-24_017050Phase 2Not yet recruiting
- Sponsor
- Verona Pharma
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nirsevimab in bronchiectasis (2 arms), sponsored by Verona Pharma. Primary endpoint: Occurrence of pulmonary exacerbations. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
nirsevimab
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on MOH_2026-09-24_017050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-09-24_017050.